This article was originally published in The Gray Sheet
Percutaneous transluminal coronary angioplasty guidewire system "designed to facilitate the exchange of over-the-wire PTCA catheters" will be launched within "the next few months," the company says. The system, comprised of the EnTre II guidewire and the Magnet exchange device, uses "magnets to maintain the position of the guidewire" during removal. The system was cleared for marketing by FDA on June 25.
You may also be interested in...
AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.
Emergency use authorization in 12-15 year-olds follows announcement of a June advisory committee meeting on pediatric data requirements, including the FDA’s criteria for younger children. Authorization for US adolescents has raised ethical questions about prioritizing this lower-risk group over hard-hit populations overseas.
Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized.